In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor- 1

Transforming growth factor1 (TGF1) has potent physiologic and pathologic effects on a variety of cell types at subnanomolar concentrations. Platelets contain 40 times as much TGF1 as other cells and secrete it as an inactive (latent) form in complex with latency-associated peptide (LAP), which is disulfide bonded via Cys33 to latent TGFbinding protein 1 (LTBP-1). Little is known about how latent TGF1 becomes activated in vivo. Here we show that TGF1 released from platelets or fibroblasts undergoes dramatic activation when subjected to stirring or shear forces, providing a potential mechanism for physiologic control. Thioldisulfide exchange appears to contribute to the process based on the effects of thiol-reactive reagents and differences in thiol labeling of TGF1 before and after stirring or shear. Activation required the presence of LTBP, as TGF1 contained in complex with only LAP could not be activated by stirring when studied as either a recombinant purified protein complex or in the platelet releasates or sera of mice engineered to contain an LAP C33S mutation. Release and activation of latent TGF1 in vivo was demonstrated in a mouse model 5 minutes after thrombus formation. These data potentially provide a novel mechanism for in vivo activation of TGF1. (Blood. 2008;112:3650-3660)

[1]  B. Hinz,et al.  Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix , 2007, The Journal of cell biology.

[2]  R. Cook,et al.  Shear-induced Disulfide Bond Formation Regulates Adhesion Activity of von Willebrand Factor* , 2007, Journal of Biological Chemistry.

[3]  Frauke Gräter,et al.  Probing the chemistry of thioredoxin catalysis with force , 2007, Nature.

[4]  Sabine Werner,et al.  Keratinocyte-fibroblast interactions in wound healing. , 2007, The Journal of investigative dermatology.

[5]  Zhiwei Yang,et al.  Absence of integrin-mediated TGFβ1 activation in vivo recapitulates the phenotype of TGFβ1-null mice , 2007, The Journal of cell biology.

[6]  D. Essex,et al.  Redox modification of platelet glycoproteins. , 2006, Current drug targets.

[7]  H. Versteeg,et al.  Disulfide isomerization switches tissue factor from coagulation to cell signaling , 2006, Proceedings of the National Academy of Sciences.

[8]  K. Huber,et al.  Predictive value of plasma plasminogen activator inhibitor‐1 for coronary restenosis: dependence on stent implantation and antithrombotic medication , 2005, Journal of thrombosis and haemostasis : JTH.

[9]  B. Coller,et al.  Antibody blockade or mutation of the fibrinogen gamma-chain C-terminus is more effective in inhibiting murine arterial thrombus formation than complete absence of fibrinogen. , 2004, Blood.

[10]  S. Barry,et al.  The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3. , 2003, The Biochemical journal.

[11]  E. Gilpin,et al.  Impact of anesthesia on cardiac function during echocardiography in mice. , 2002, American journal of physiology. Heart and circulatory physiology.

[12]  S. Gando Disseminated Intravascular Coagulation in Trauma Patients , 2001, Seminars in thrombosis and hemostasis.

[13]  N. Aikawa,et al.  Elevation of plasma free PAI-1 levels as an integrated endothelial response to severe burns. , 2001, Burns : journal of the International Society for Burn Injuries.

[14]  A. Ludlow,et al.  Activation of Platelet-transforming Growth Factor β-1 in the Absence of Thrombospondin-1* , 2000, The Journal of Biological Chemistry.

[15]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[16]  E. Topol,et al.  Recognition of the importance of embolization in atherosclerotic vascular disease. , 2000, Circulation.

[17]  S. Alper,et al.  Hemodynamic shear stress and its role in atherosclerosis. , 1999, JAMA.

[18]  B. Coller,et al.  Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alphaIIbbeta3) and other proteins from hamster-mouse interspecies hybridomas. , 1999, Biochemical and biophysical research communications.

[19]  N. Kaminski,et al.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.

[20]  M. Fishbein,et al.  Characteristics of wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy: role of increased fibrosis in the generation of reentry. , 1998, Journal of the American College of Cardiology.

[21]  R. Beyar,et al.  Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. , 1998, American heart journal.

[22]  R. Busse,et al.  Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB. , 1997, Circulation.

[23]  C. Bredahl,et al.  Plasminogen activators and plasminogen activator inhibitor before and after surgery in patients with and without gastric malignancy. , 1995, Haemostasis.

[24]  L. Wakefield,et al.  Release and activation of platelet latent TGF–β in blood clots during dissolution with plasmin , 1995, Nature Medicine.

[25]  D. Rifkin,et al.  An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. , 1994, Analytical biochemistry.

[26]  M. Sporn,et al.  Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[28]  E. Holler,et al.  Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha (TNF alpha)-release in patients suffering from microangiopathy following allogeneic bone marrow transplantation (BMT). , 1992, Thrombosis research.

[29]  P. Browne,et al.  Complexes of Thrombin with Proteins Secreted by Activated Platelets , 1992, Seminars in thrombosis and hemostasis.

[30]  D. Loskutoff,et al.  Platelets stimulate endothelial cells to synthesize type 1 plasminogen activator inhibitor. Evaluation of the role of transforming growth factor beta. , 1991, Blood.

[31]  Sporn,et al.  Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. , 1988, The Journal of biological chemistry.

[32]  K. Miyazono,et al.  Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. , 1988, The Journal of biological chemistry.

[33]  M. Sporn,et al.  Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells , 1986, The Journal of cell biology.

[34]  D. Lawrence,et al.  Latent beta-transforming growth factor in nontransformed and Kirsten sarcoma virus-transformed normal rat kidney cells, clone 49F. , 1984, Cancer research.

[35]  M. Sporn,et al.  Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. , 1983, The Journal of biological chemistry.

[36]  A. Cumano,et al.  Forced Unfolding of Proteins Within Cells , 2007 .

[37]  F. Verrecchia,et al.  Transforming growth factor-beta and fibrosis. , 2007, World journal of gastroenterology.

[38]  J. Bluestone,et al.  Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. , 2007, Nature.

[39]  H. von Melchner,et al.  TGF-beta activation by traction? , 2004, Trends in cell biology.

[40]  A. Ludlow,et al.  Latent TGF-beta1 activation by platelets. , 2004, Journal of cellular physiology.

[41]  D. Essex,et al.  Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin alpha2beta1. , 2003, Blood.

[42]  D. Rifkin,et al.  Making sense of latent TGFbeta activation. , 2003, Journal of cell science.

[43]  Jeffrey W. Smith,et al.  Redox control of integrin adhesion receptors. , 2002, Methods in enzymology.

[44]  J. Massagué TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[45]  D. Wilcken,et al.  Circulating transforming growth factor beta 1 and coronary artery disease. , 1997, Cardiovascular research.

[46]  J. Verheijen,et al.  The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. , 1985, Scandinavian journal of clinical and laboratory investigation.